Clinical Trials Logo

Diabetic Retinopathy clinical trials

View clinical trials related to Diabetic Retinopathy.

Filter by:

NCT ID: NCT00797524 Completed - Clinical trials for Diabetic Retinopathy

Function and Structure Imaging in Different Retinal Diseases: Retinal Leakage Analyzer Versus Optical Coherence Tomography

Start date: November 2008
Phase: N/A
Study type: Observational

The main objective of this observational study is to characterize and correlate functional and structural changes at the retinal level using the Retinal Leakage Analyzer (RLA) and the Optical Coherence Tomograph (OCT). To show if it is possible to use OCT as an indirect measurement of leakage, this study will check, in a primary analysis, for OCT changes between fluorescein leaking and non-leaking areas (identified by Retinal Leakage Analyzer). As a secondary objective, changes in RLA and OCT over time (between two consecutive visits) will be analyzed and characterized. The results of this study will be used exclusively for scientific purposes.

NCT ID: NCT00797134 Completed - Clinical trials for Diabetic Retinopathy

Retinal Thickness Analysis Using Optical Coherence Tomography

Start date: November 2008
Phase: N/A
Study type: Observational

The main objective of this study is to characterize and correlate diabetic macular edema (DME), i.e. increased retinal thickness, measured by Optical Coherence Tomograph (OCT), and retinal visual function. The secondary objectives of this study are the analysis and characterization of DME progression over time (between two visits), and the comparison of OCT data obtained with different devices. The results of this study will be used exclusively for scientific purposes.

NCT ID: NCT00782717 Completed - Macular Edema Clinical Trials

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.

NCT ID: NCT00776763 Completed - Clinical trials for Age Related Macular Degeneration

Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab

KIA-ProRet
Start date: October 2008
Phase: Phase 2
Study type: Interventional

Aims of the trial: Establishing the profile of the growth factors and other mediators of angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in vitrectomized eyes), in the 2 most frequent proliferative retinopathies - diabetic proliferative retinopathy (PDR) and exudative age related macular degeneration (AMD). Following up the dynamic of this profile before and after intravitreal administration of Bevacizumab (Avastin) as an anti-VEGF blocker. Materials: The research will be conducted on the following categories of patients groups: - nondiabetic patients without AMD or any other diagnosed proliferative ocular disease (controls) - patients with age related macular degeneration (AMD groups) before and after intravitreal injections with Avastin - diabetic patients with different types of diabetic retinopathy, before and after intravitreal Avastin (diabetic groups) Methods: Samples from different ocular fluids will be collected from each group of patients. 10 growth factors and other 10 cytokines will be determined in the ocular fluids samples. Results: The results from the biochemical measurements will be statistically interpreted in order to obtain conclusions for the clinical practice. Conclusions: The conclusions of this trial will be used exclusively for research publications and communications, as well as for clinical practice.

NCT ID: NCT00763802 Completed - Clinical trials for Diabetic Retinopathy

Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2

CPM
Start date: September 2007
Phase: N/A
Study type: Observational

This project aims to validate a predictive model of diabetic retinopathy progression to clinically significant macular edema (CSME) needing photocoagulation and/or vision loss. The Coimbra Predictive Model (CPM), based on retinal thickness, microaneurysms number, HbA1C and LDL levels, established on a set of 52 diabetic patients, will be tested on a population of 400 patients/eyes to be enrolled into the study. These patients will perform 2 visits at 6-month interval (V0 and V6) to classify each patient into one of the 3 previously established phenotypes. Two years after (V24) patients will be reexamined. The occurrence of end-points, achieved by the patients, are expected to validate our predictive model.

NCT ID: NCT00745498 Completed - Clinical trials for Proliferative Diabetic Retinopathy

Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy

IBDV
Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.

NCT ID: NCT00737074 Completed - Clinical trials for Proliferative Diabetic Retinopathy

Macular Hole in Diabetic Retinopathy

Start date: January 2002
Phase: N/A
Study type: Observational

Macular hole in proliferative diabetic retinopathy with fibrovascular proliferation may have unique features. Internal limiting membrane peeling facilitates hole closure only in cases with shallow macular detachment. Final vision is associated with preoperative visual acuity and degree of macula elevation.

NCT ID: NCT00737022 Completed - Clinical trials for Proliferative Diabetic Retinopathy

Macular Appearance After Diabetic Vitrectomy

Start date: May 2005
Phase: N/A
Study type: Observational

Vitrectomy is one of the major treatment methods for complications of diabetic retinopathy. As surgical techniques and instruments improve, high anatomical success may be achieved; however, functional results are less favorable. Despite attached retina, postoperative visual function may be affected by various macular and disc abnormalities. Major changes include optic atrophy, atrophic retina, poor macular perfusion, and structural alternations of the macula. Funduscopy, fluorescein angiography, and, more recently, optical coherence tomography (OCT) can be used to detect and document these alterations. Although fluorescein angiography is valuable in the assessment of various macular lesions as well as retinal vascular abnormalities, its usefulness in evaluating macular changes is limited in eyes that have undergone diabetic vitrectomy. The quality of the images may be compromised by mild diffuse hyperfluorescence in the posterior pole in middle and late phase angiography, which obscures capillary detail and subtle macular changes. Furthermore, quantification of changes may not be possible. Recently, optical coherence tomography has become very useful for the detection of vitreomacular abnormalities. The examination is noninvasive, can qualify the changes and detect subtle abnormalities not evident with other imaging studies. In this study, OCT was applied to investigate how common macular structure abnormalities are present after surgery for complications of diabetic retinopathy, and how they may affect visual prognosis.

NCT ID: NCT00728598 Completed - Clinical trials for Proliferative Diabetic Retinopathy

Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis

Start date: January 1998
Phase: N/A
Study type: Observational

Fractalkine (FKN) is a chemoattractant and adhesion molecule for leukocytes. Angiogenic effect of FKN also has been reported. We investigate FKN-mediated angiogenesis in ocular angiogenic disorders.

NCT ID: NCT00720317 Completed - Clinical trials for Diabetic Retinopathy

Diabetic Retinopathy and Sickle Trait

Start date: May 2008
Phase: N/A
Study type: Observational

To more clearly ascertain the relationship between ocular manifestations of sickle cell disease and diabetes, specifically; whether the presence of sickle cell trait exacerbates the disease progression of diabetic retinopathy.